Involvement of nucleoside diphosphate kinase b and elongation factor 2 in Leishmania braziliensis antimony resistance phenotype by Douglas S. Moreira & Silvane M. F. Murta
RESEARCH Open Access
Involvement of nucleoside diphosphate
kinase b and elongation factor 2 in
Leishmania braziliensis antimony resistance
phenotype
Douglas S. Moreira and Silvane M. F. Murta*
Abstract
Background: Nucleoside diphosphate kinase b (NDKb) is responsible for nucleoside triphosphates synthesis and it
has key role in the purine metabolism in trypanosomatid protozoans. Elongation factor 2 (EF2) is an important
factor for protein synthesis. Recently, our phosphoproteomic analysis demonstrated that NDKb and EF2 proteins
were phosphorylated and dephosphorylated in antimony (SbIII)-resistant L. braziliensis line compared to its SbIII-
susceptible pair, respectively.
Methods: In this study, the overexpression of NDKb and EF2 genes in L. braziliensis and L. infantum was performed
to investigate the contribution of these proteins in the SbIII-resistance phenotype. Furthermore, we examined the
role of lamivudine on SbIII susceptibility in clones that overexpress the NDKb gene, and the effect of EF2 kinase
(EF2K) inhibitor on the growth of EF2-overexpressing parasites.
Results: Western blot analysis demonstrated that NDKb and EF2 proteins are more and less expressed, respectively,
in SbIII-resistant line of L. braziliensis than its wild-type (WTS) counterpart, corroborating our previous
phosphoproteomic data. NDKb or EF2-overexpressing L. braziliensis lines were 1.6 to 2.1-fold more resistant to SbIII
than the untransfected WTS line. In contrast, no difference in SbIII susceptibility was observed in L. infantum
parasites overexpressing NDKb or EF2. Susceptibility assays showed that NDKb-overexpressing L. braziliensis lines
presented elevated resistance to lamivudine, an antiviral agent, but it did not alter the leishmanicidal activity in
association with SbIII. EF2-overexpressing L. braziliensis clone was slightly more resistant to EF2K inhibitor than the
WTS line. Surprisingly, this inhibitor increased the antileishmanial effect of SbIII, suggesting that this association
might be a valuable strategy for leishmaniasis chemotherapy.
Conclusion: Our findings represent the first study of NDKb and EF2 genes overexpression that demonstrates an
increase of SbIII resistance in L. braziliensis which can contribute to develop new strategies for leishmaniasis
treatment.
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Background
Leishmaniasis refers to a disease complex caused by
protozoan Leishmania parasites which are transmitted
to humans by the bite of infected female phlebotomine
sandflies. According to the World Health Organization
(WHO), leishmaniasis is a neglected tropical disease that
constitutes a public health problem in many developing
countries of the Indian subcontinent, Latin America and
East Africa [1]. Human leishmaniasis has an incidence of
1.2 million new cases annually, with an estimated popu-
lation of 350 million at risk and a prevalence of 12 mil-
lion cases [2]. Depending on genetic and environmental
factors, the host immune response and mainly on Leish-
mania species involved, the disease can comprise three
main clinical manifestations: cutaneous (CL), mucocuta-
neous (MCL) or visceral (VL) [3]. In the New World, L.
(Viannia) braziliensis is the causative agent of CL and
MCL, whereas L. (Leishmania) infantum [syn. L. (L.)
chagasi] causes VL, which is lethal if not treated [4, 5].
Pentavalent antimonials (SbV), such as sodium stibo-
gluconate (Pentostam®) and meglumine antimoniate
(Glucantime®), remain the first-line of treatment against
all forms of the disease for more than 70 years especially
in developing countries [6]. Despite the mechanism of
antimony action has not been completely elucidated,
studies suggest that SbV is reduced to trivalent form
(SbIII) that is active against amastigote and promastigote
forms of Leishmania [7]. Earlier reports have indicated
that antimonials inhibit fatty acid β-oxidation and
glycolysis [8], and cause perturbations in the thiol redox
potential, which would drive to parasite death by oxida-
tive stress [9]. Furthermore, it has been suggested that
antimony can kill the parasite by an apoptosis process
resulting in DNA fragmentation and externalization of
phosphatidylserine outside of Leishmania [10, 11].
The emergence and spread of resistance to antimony
is significant in determined regions, such as Bihar state
in India where over 60% of VL patients do not respond
to the traditional therapy using antimonials [12]. Recent
studies have demonstrated several mechanisms in Leish-
mania species implicated in resistance to these com-
pounds. Thus, antimony resistance constitutes a
multifactorial process and involves at least some of
following aspects. A decrease in rate of reduction from
pentavalent to trivalent form or loss of reductase activity
may lead to drug resistance [13, 14]. Lower expression
of AQP1 (aquaglyceroporin), which is involved in SbIII
uptake into parasite, was also observed in resistant
mutants [15, 16]. Increased levels of intracellular thiols
were found in cells selected for resistance to SbIII [17] as
well as in unresponsive clinical isolates [18–20]. MRPA
(multidrug resistance associated protein A) transporter
confers resistance by sequestering thiol-Sb conjugates
into an intracellular vacuole which removes the drug
from the cytoplasm of the parasite [21]. An increase of
PGP (phosphoglycoprotein) expression was described in
Leishmania resistant to antimonials [22], suggesting that
this protein mediates the efflux of these drugs from the
parasite. Moreover, other mechanisms can also contrib-
ute to the antimony resistance phenotype in Leishmania.
Nucleoside diphosphate kinase b (NDKb), a NDK
family member, is ubiquitous enzyme that is crucial to
transfer phosphate group from a nucleoside triphosphate
(NTP) to a nucleoside diphosphate (NDP), using a ping-
pong mechanism that involves a phosphohistidine
intermediate [23, 24]. The whole reaction is described as
follows [25]:
NDKþN1TP↔ NDK‐P þ N1DP↔ NDK‐P
þ N2DP↔ NDK þ N2TP
NDKs play pivotal roles in different organisms, such as
in bacterial pathogenesis [26], regulation of gene expres-
sion in cells of mammals [27] and participation in the
purine salvage pathways of protozoan parasites [28].
NTP is a precursor for DNA and RNA synthesis, eviden-
cing that NDK is also an essential enzyme for all cellular
processes involving nucleic acids in distinct species of
organisms [24]. Unlike mammals, Leishmania is not able
to synthesize purines by means of a de novo mechanism
and thus depend upon the host for survival [29]. Kolli et
al. [30] showed that Leishmania-released NDK avoids
ATP-mediated lysis of macrophages, keeping the integ-
rity of host cells to the advantage of the parasite. There-
fore, NDKb can be considered an interesting target for
drug discovery for chemotherapy of leishmaniasis.
The regulation of protein synthesis in eukaryotic cells
occurs via both initiation and elongation levels. This
process uses significant quantity of cellular energy, and
the vast majority of this is consumed in elongation [31].
Elongation factor 2 (EF2) codifies a member of the GTP-
binding translation elongation factor family and it is a
relevant factor for production of proteins. EF2, which is
a ubiquitous enzyme, makes the GTP-dependent trans-
location of the aminoacyl-tRNA from the A-site to the
P-site of the ribosome [32]. EF2 protein was found with
increased abundance in promastigote forms of L. pana-
mensis resistant to SbIII [33].
Considering the multiplicity of antimony resistance
mechanisms, our knowledge about them in New World
Leishmania species is far from being fully elucidated.
Recently, our phosphoproteomic analysis demonstrated
that the nucleoside diphosphate kinase b (NDKb) and
elongation factor 2 (EF2) proteins were phosphorylated
and dephosphorylated, respectively, in SbIII-resistant L.
braziliensis line compared to its wild-type (WTS) coun-
terpart [34]. In this study, NDKb and EF2 genes were
transfected in SbIII-susceptible lines of L. braziliensis and
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L. infantum to determine whether the overexpression of
these proteins contributes to antimony resistance pheno-
type in these parasites. Moreover, we investigated the
role of lamivudine on SbIII susceptibility in NDKb-
overexpressing clones, and the effect of EF2 kinase




We used promastigote forms of L. braziliensis (MHOM/
BR/75/M2904) and L. infantum (MHOM/BR/74/PP75)
in our study. The antimony-resistant lines were previ-
ously selected in vitro to potassium antimonyl tartrate
(SbIII) (C8H4K2O12Sb2.3H2O) by step-wise drug pressure
and their resistance indices were 20-fold and 4-fold
higher than those of their wild-type counterparts,
respectively [35]. Parasites were grown at 26 °C in M199
medium supplemented with 2 mM L-glutamine, 5 μg/ml
hemin, 50 μg/ml streptomycin, 2 μg/ml biopterin, 1 μg/
ml biotin, 40 mM HEPES pH 7.4, 500 U penicillin and
10% v/v heat-inactivated fetal calf serum [35]. These
parasites were harvested in the logarithmic growth phase
to perform all analyses.
Generation of NDKb and EF2 overexpressing lines
A 456 bp fragment corresponding to NDKb encoding
region (TriTrypDB accession number LbrM.32.3210)
was amplified with Pfx DNA polymerase (Invitrogen)
from L. braziliensis genomic DNA using the forward pri-
mer: 5′-TGG ATC CCC ACC ATG TCC TCC GAG
CGC ACT TT-3′ and the reverse primer: 5′-TTG GAT
CCC TAT TCG TAG ATC TGG CAA GCG G-3′.
Other 2,538 bp fragment corresponding to EF2 encoding
region (TriTrypDB accession number LbrM.35.0270)
was also amplified with the enzyme cited above using L.
braziliensis genomic DNA and the primers forward: 5′-
TGG ATC CCC ACC ATG GTG AAC TTT ACC GTC
GAT CAG-3′ and reverse: 5′-TTG GAT CCT TAC
AAT TTA TCC ATG AAC TGG TCC A-3′. The under-
lined sequences correspond to BamHI restriction site.
The obtained PCR products were cloned into the
pGEM-T Easy® vector (Promega, Madison, WI, USA)
and subsequently submitted to sequencing reaction for
confirmation of correct sequence. All constructs were
sequenced in an ABI 3130 (Applied Biosystems, Foster
City, CA, USA). The pGEM-NDKb and pGEM-EF2
constructs were restricted with BamHI and the frag-
ments released were subcloned into the dephosphory-
lated pIR1BSD expression vector (kindly provided by Dr.
Stephen Beverley, Washington University, USA). To
confirm the correct direction of cloning, the constructs
were then digested with HindIII and SmaI releasing frag-
ments that confirmed the sense direction of the genes
NDKb and EF2, respectively. Thus, the constructs
pIR1BSD (empty vector), pIR1BSD-NDKb and
pIR1BSD-EF2 were linearized by SwaI digestion and
electroporated into wild-type L. braziliensis and L. infan-
tum lines using a GenePulser XCell electroporation
system (Bio-Rad, Hercules, CA, USA). This allowed inte-
gration of the vector into the 18S ribosomal DNA small
subunit locus [36]. Colonies were obtained following
plating on semisolid M199 medium containing blastici-
din (BSD) (10 μg/ml). After 1–2 weeks, clonal lines were
selected and the presence of constructs was confirmed
by PCR tests using genomic DNA with primers specific
for the BSD marker.
Protein levels
Western blot assays were carried out for investigating
the expression level of NDKb and EF2 proteins in the
transfected parasites and in the SbIII-resistant and -sus-
ceptible lines of L. braziliensis and L. infantum. Total
proteins from these parasites were extracted according
to the protocol previously described [37]. Subsequently,
20 μg from each sample were separated by electrophor-
esis on 12% SDS-polyacrylamide gel and transferred
onto nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA). They were blocked, washed and probed with
rabbit polyclonal anti-NDKb (1:200) (Abcam, Cam-
bridge, UK, #ab154274) or rabbit monoclonal anti-EF2
(1:200) (Abcam, Cambridge, UK, #ab75748) antibodies,
during 12 h at 4 °C in the blocking solution. According
to manufacturer specifications, the immunogen of the
first antibody is a recombinant fragment corresponding
to a region within amino acids 1–105 of human NDKb,
while the immunogen of the second antibody is a syn-
thetic peptide corresponding to residues on the C ter-
minal of human EF2 (Abcam, Cambridge, UK). The
blots were washed twice and incubated with horseradish
peroxidase-conjugated anti-rabbit IgG (1:5,000) (GE
Healthcare) for 1 h at room temperature. After incuba-
tion, the membranes were washed, incubated with ECL
Plus chemiluminescent substrate (GE Healthcare) and
revealed by ImageQuant LAS 4000 (GE Healthcare). To
confirm equivalent loading, SDS-PAGE containing the
samples were stained with Coomassie blue. Furthermore,
the blots were normalized using the antibody monoclo-
nal anti-α-tubulin (1:15,000) (Sigma, St. Louis, USA).
The intensity of the bands was analyzed using the soft-
ware GelAnalyzer 2010 (gelanalyzer.com).
Susceptibility assays of Leishmania spp. clonal lines to
SbIII and H2O2
Promastigotes of wild-type L. braziliensis and L. infan-
tum clonal lines non-transfected or transfected with the
constructs pIR1BSD (empty vector), pIR1BSD-NDKb or
pIR1BSD-EF2 were submitted to SbIII (Sigma-Aldrich,
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St. Louis, MO, USA) susceptibility tests. The susceptibil-
ity to hydrogen peroxide (H2O2) was also evaluated in
the parasites transfected with the NDKb gene. Parasites
were incubated in M199 medium at 2 × 106 cells/ml into
24-well plates in the absence or presence of several con-
centrations of SbIII (1.17 to 599.04 μM which corre-
sponds to 0.00078125 to 0.4 mg/ml) or H2O2 (100 to
350 μM) for 48 h. The effective concentration required
to decrease growth by 50% (EC50) was determined using
a model Z1 Coulter Counter (Beckman Coulter, Fuller-
ton, CA, USA). EC50 values were determined from at
least three independent measurements performed in
triplicate, using the linear interpolation method [38].
Susceptibility assays of L. braziliensis lines to lamivudine
and EF2K inhibitor and competition assays
We determined the susceptibility of L. braziliensis lines to
lamivudine (2′,3′-dideoxy-3′-thiacytidine - C8H11N3O3S)
(Globe Química) (kindly provided by Dr. Juliana Medeiros
and Dr. Ana Cláudia Tavares, Farmanguinhos/FIOCRUZ,
Brazil) and 7-Amino-1-cyclopropyl-3-ethyl-1,2,3,4-tetra-
hydro-2,4-dioxopyrido [2,3-d] pyrimidine-6-carboxamide
(C13H15N5O3) (Tocris Bioscience, A484954) which are in-
hibitors for the enzymes NDKb and elongation factor 2
kinase (EF2K), respectively. EC50 of these inhibitors for
wild-type L. braziliensis line and parasites that overexpress
the NDKb or EF2 genes was determined to be used in
competition tests with SbIII. The cultures (2 × 106 cells/
ml) were incubated in the absence or presence of various
concentrations of lamivudine (125 to 10,000 μM) or EF2K
inhibitor (50 to 300 μM) into 24-well plates during 48 h.
After, the percentage of relative growth was determined
by automated cell counting. Competition assays were
performed to investigate the leishmanicidal activity of the
inhibitors cited above in association with SbIII. In these ex-
periments, 2 × 106 parasites/ml were seeded into 24-well
cell culture plates containing medium M199. Subse-
quently, the EC50 of lamivudine and EF2K inhibitor were
added concomitantly with SbIII EC50 (Table 1), followed
by incubation for 48 h. The percentage of relative growth
was determined by automated cell counting using a Z1
Coulter Counter.
Statistical analysis
Data were analyzed by Student’s t-test performed using
the software GraphPad Prism 5.0. A P-value less than
0.05 was considered statistically significant.
Results
Expression levels of NDKb and EF2 proteins in Leishmania
lines
We determined the expression levels of the proteins
NDKb and EF2 in the antimony-susceptible and
antimony-resistant L. braziliensis and L. infantum lines
by Western blot analysis using polyclonal anti-NDKb
and monoclonal anti-EF2 antibodies, respectively. These
antibodies are specific for mammalian proteins. It is im-
portant to highlight that the identity between the NDKb
and EF2 amino acid sequences of L. braziliensis com-
pared to mammalian was 66 and 61%, respectively (data
not shown). Western blot results revealed that these
antibodies recognized polypeptides of 17 kDa and
94 kDa in all Leishmania samples analyzed which
correspond to the expected size of NDKb and EF2 pro-
teins, respectively (Fig. 1a). The membranes were incu-
bated with the monoclonal anti-α-tubulin antibody for
normalization of the results (Fig. 1a). The expression
level of NDKb protein was 1.5-fold and 2.4-fold higher
in the SbIII-resistant Leishmania spp. lines (LbSbR and
LiSbR) in comparison with their respective wild-type
lines (LbWTS and LiWTS) (Fig. 1a). Regarding expres-
sion level of EF2 protein, the results demonstrated that
this protein was approximately 3-fold lower in the SbIII-
resistant L. braziliensis line when compared to its wild-
type counterpart LbWTS. On the other hand, the EF2
Table 1 EC50 of Sb
III, lamivudine, EF2K inhibitor and hydrogen peroxide and corresponding RI for WTS, NDKb- or EF2-overexpressing
L. braziliensis lines. EC50 represents effective concentration required to decrease growth by 50%. The values were determined from at
least three independent experiments performed in triplicate, using the linear interpolation method [38]
Parasites SbIII Lamivudine EF2K inhibitor Hydrogen peroxide
EC50 (μM) RI EC50 (μM) RI EC50 (μM) RI EC50 (μM) RI
LbWTS 7 – 766 – 173 – 213 –
LbpIR1BSD 8 – 733 – – – 207 –
LbNDKb clone 4 12 1.7 2,110 2.8 – – 207 1.0
LbNDKb clone 9 15 2.1 2,014 2.6 – – 207 1.0
LbEF2 clone 9 14 2.0 – – 211 1.2 – –
LbEF2 clone 12 11 1.6 – – – – – –
Chemical formulae and abbreviations: SbIII (potassium antimonyl tartrate); lamivudine (C8H11N3O3S); EF2K inhibitor (C13H15N5O3); hydrogen peroxide (H2O2); WTS
wild-type susceptible, Lb L. (V.) braziliensis, pIR1BSD expression vector, NDKb nucleoside diphosphate kinase b, EF2 elongation factor 2, EF2K elongation factor 2
kinase, RI resistance index
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Fig. 1 NDKb and EF2 expression levels in wild-type (WTS), SbIII-resistant (SbR) and clonal lines from L. braziliensis and L. infantum untransfected or
transfected with the constructs pIR1BSD (empty vector), pIR1BSD-NDKb or pIR1BSD-EF2. Total proteins (20 μg) were separated by electrophoresis
on 12% SDS-polyacrylamide gel and transferred onto nitrocellulose membranes. The profiles of total proteins stained with Coomassie blue are
shown. The blots were probed with rabbit polyclonal anti-NDKb (1:200) (a, b and c) or rabbit monoclonal anti-EF2 (1:200) (a, d and e) antibodies
and developed using ECL Plus kit. All membranes were incubated with the anti-α-tubulin monoclonal (1:15,000) antibody for normalization of the
results. Quantification of the bands was done by densitometric analysis using the software GelAnalyzer 2010. The figure is representative of all
results obtained from two different biological replicates of each sample. The values of each replicate were used to calculate the averages and for
determination of the ratios presented for each protein analyzed
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protein presented the same level of expression between
the LiWTS and LiSbR lines (Fig. 1a).
Overexpression of NDKb and EF2 genes in L. braziliensis
and L. infantum
Wild-type L. braziliensis and L. infantum lines were
transfected with the constructs containing the NDKb or
EF2 genes (pIR1BSD-NDKb or pIR1BSD-EF2) and
empty vector (pIR1BSD) to generate parasites overex-
pressing the enzymes NDKb and EF2. Linearization of
this vector allowed integration of the constructs into the
ribosomal small subunit locus [36]. To confirm the
transfection, genomic DNA from the transfected clones
was subjected to PCR assays using specific primers for
the BSD gene, which confers resistance to blasticidin. It
was observed that all blasticidin-resistant clones showed
a fragment of 399 bp, which corresponds to BSD marker
(data not shown). These clones were subjected to
Western blot assays in order to evaluate if the NDKb
and EF2 enzymes were overexpressed. Our results
showed that the level of NDKb protein expression was
1.5 to 4.4-fold higher in the transfected clones from L.
braziliensis and L. infantum lines than in the non-
transfected or transfected with empty vector (controls)
(Fig. 1b, c). Furthermore, our analysis also demonstrated
that the expression level of EF2 protein was increased
1.7 to 3.6-fold in the transfected clones from these both
wild-type Leishmania lines when compared to their
respective controls (Fig. 1d, e).
Susceptibility of NDKb and EF2 overexpressing
Leishmania spp. lines to SbIII
We also investigated whether the overexpression of
NDKb and EF2 genes contributes to antimony resistance
phenotype in Leishmania. For this, clonal lines from L.
braziliensis and L. infantum transfected with the con-
structs pIR1BSD (empty vector), pIR1BSD-NDKb or
pIR1BSD-EF2 and untransfected parasites were incu-
bated with different SbIII concentrations. The EC50 was
determined by counting of parasites number grown in
the absence or presence of this drug. The results showed
that the SbIII EC50 of untransfected L. braziliensis line
was 7 μM. On the other hand, the clones 4 and 9 that
overexpress NDKb in this Leishmania species presented
EC50 of 12 μM and 15 μM, demonstrating an increase of
1.7 and 2.1-fold in the SbIII resistance index of these
clones, respectively (Fig. 2a) (Table 1). In contrast,
NDKb-overexpressing L. infantum lines did not show an
increase in resistance towards SbIII. The results revealed
that the SbIII EC50 of wild-type L. infantum line was
67 μM, and the NDKb overexpressing clones 1 and 19
was 81 and 73 μM, respectively (Fig. 2b).
Regarding EF2 gene, we observed that SbIII EC50 of
EF2-overexpressing clones 9 and 12 in L. braziliensis
was 14 μM and 11 μM, showing an increase of 2.0 and
1.6-fold in the resistance index of SbIII of these clones,
respectively (Fig. 3a) (Table 1). On the other hand, EF2-
overexpressing L. infantum lines did not alter the SbIII
susceptibility. The SbIII EC50 of EF2-overexpressing
clones 5 and 7 was 80 μM and 67 μM, respectively
(Fig. 3b).
It is important to mention that NDKb- or EF2-
overexpressing parasites presented similar growth curves
when compared with their respective controls for both
Leishmania species (data not shown). In the SbIII sus-
ceptibility assays, we observed gradual reduction in the
growth of NDKb- or EF2-overexpressing parasites of L.
braziliensis with increasing drug concentrations. In
Fig. 2 SbIII susceptibility assay of clonal lines from L. braziliensis (a) and L. infantum (b) non-transfected or transfected with the constructs pIR1BSD
or pIR1BSD-NDKb. Parasites were incubated in M199 medium in the absence or presence of different concentrations of SbIII (1.17 to 599.04 μM)
for 48 h and the percentage of relative growth was determined using a Z1 Coulter Counter. Mean values ± standard deviations from three
independent experiments in triplicate are shown. Statistical analysis was carried out using Student’s t-test. Statistically different values are
highlighted as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Pairwise comparisons (a): 1.17 μM: LbWTS vs LbNDKb clone 4 (t(5) = 9.47, P = 0.0002);
LbWTS vs LbNDKb clone 9 (t(9) = 3.36, P = 0.0084); 2.34 μM: LbWTS vs LbNDKb clone 4 (t(5) = 4.3, P = 0.0077); LbWTS vs LbNDKb clone 9 (t(8) = 3.74,
P = 0.0057); 4.68 μM: LbWTS vs LbNDKb clone 4 (t(4) = 4.02, P = 0.0159); LbWTS vs LbNDKb clone 9 (t(5) = 4.99, P = 0.0042); 9.36 μM: LbWTS vs
LbNDKb clone 4 (t(6) = 8.39, P = 0.0002); LbWTS vs LbNDKb clone 9 (t(8) = 12.50, P < 0.0001); 18.72 μM: LbWTS vs LbNDKb clone 4
(t(8) = 2.88, P = 0.0206); LbWTS vs LbNDKb clone 9 (t(10) = 7.36, P < 0.0001)
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addition, we observed that the overexpressors of NDKb
or EF2 were more resistant to SbIII until concentrations
near to EC50 of these clones. In higher antimony
concentrations, these parasites presented similar growth
to their controls. We also observed that the vector used
in our assays did not interfere in the SbIII susceptibility
since no difference in SbIII EC50 was observed between
parasites untransfected and transfected with empty
vector.
Effect of lamivudine on the growth of wild-type and
NDKb-overexpressing L. braziliensis lines
Initially, the amino acid sequence of NDKb (TriTrypDB
accession number LbrM.32.3210) was used to search
possible drugs against this enzyme in the DrugBank
(www.drugbank.ca). Search results for the submitted se-
quence returned three antiviral agents: tenofovir (ID
DB00300), lamivudine (ID DB00709) and adefovir dipi-
voxil (ID DB00718). These drugs are recommended in
the chemotherapy of chronic hepatitis B (HBV), and the
first two are also useful to treat HIV infection. Lamivu-
dine is a synthetic nucleoside analogue and is phosphor-
ylated intracellularly to its active 5′-triphosphate
metabolite (lamivudine triphosphate - LTP), which is
included into viral DNA by HIV reverse transcriptase
and HBV polymerase, causing the ending of DNA chain
(www.drugbank.ca/drugs/DB00709). We determined the
lamivudine EC50 of wild-type L. braziliensis line and par-
asites transfected with the constructs pIR1BSD (empty
vector) and pIR1BSD-NDKb. Our data showed that the
lamivudine EC50 were 2.6-fold and 2.8-fold higher for
NDKb-overexpressing clones 9 and 4 (2,014 and
2,110 μM, respectively) when compared to LbWTS
(766 μM) (Fig. 4a) (Table 1), demonstrating that these
clones are more resistant to lamivudine. Competition
assay was carried out to analyze the combination of
lamivudine and SbIII treatment in WTS and NDKb-
overexpressing L. braziliensis lines. Then, the parasites
were incubated simultaneously with their respective
EC50 for each drug (Table 1), and after 48 h the relative
growth of the parasites was calculated. The combined ef-
fect of both compounds reduced by 55%, 59.7% and
63.7%, respectively, parasite numbers of LbWTS,
LbNDKb clones 4 and 9, showing that the lamivudine
did not increase the leishmanicidal activity of SbIII
(Fig. 4b).
Effect of EF2K inhibitor on the growth of wild-type and
EF2-overexpressing L. braziliensis lines
Elongation factor 2 kinase (EF2K), a calmodulin-
dependent protein, binds numerous up-stream signals
to the regulation of protein synthesis. Thus, EF2K
phosphorylates EF2 and inhibits the function of this
enzyme [39]. Chen et al. [40] showed that inhibition of
EF2K by EF2K inhibitor decreases EF2 phosphoryl-
ation however it has little effect on proliferation in the
cancer cells. Then, we tested the potential leishmanici-
dal effect of this inhibitor against wild-type and EF2-
overexpressing L. braziliensis lines. Incubation of par-
asites with different concentrations of EF2K inhibitor
revealed that the EC50 of this drug was 1.2-fold higher
for LbEF2 clone 9 (211 μM) in comparison with
LbWTS (173 μM) (Fig. 5a) (Table 1). This result shows
that the overexpression of EF2 enzyme protects
Fig. 3 SbIII susceptibility assay of clonal lines from L. braziliensis (a) and L. infantum (b) non-transfected or transfected with the constructs pIR1BSD
or pIR1BSD-EF2. Parasites were incubated in M199 medium in the absence or presence of different concentrations of SbIII (1.17 to 599.04 μM) for
48 h and the percentage of relative growth was determined using a Z1 Coulter Counter. Mean values ± standard deviations from three
independent experiments in triplicate are shown. Statistical analysis was carried out using Student’s t-test. Statistically different values are
highlighted as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Pairwise comparisons (a): 1.17 μM: LbWTS vs LbEF2 clone 9 (t(9) = 6.5, P = 0.0001); LbWTS
vs LbEF2 clone 12 (t(5) = 2.84, P = 0.0361); 2.34 μM: LbWTS vs LbEF2 clone 9 (t(7) = 6.95, P = 0.0002); LbWTS vs LbEF2 clone 12 (t(4) = 2.87, P =
0.0455); 4.68 μM: LbWTS vs LbEF2 clone 9 (t(5) = 6.04, P = 0.0018); LbWTS vs LbEF2 clone 12 (t(4) = 2.87, P = 0.0453); 9.36 μM: LbWTS vs LbEF2 clone
9 (t(7) = 22.18, P < 0.0001); LbWTS vs LbEF2 clone 12 (t(8) = 4.48, P = 0.0021); 18.72 μM: LbWTS vs LbEF2 clone 9 (t(11) = 4.74, P = 0.0006); LbWTS vs.
LbEF2 clone 12 (t(9) = 7.65, P < 0.0001); 37.44 μM: LbWTS vs LbEF2 clone 9 (t(5) = 2.78, P = 0.0391); LbWTS vs LbEF2 clone 12 (t(5) = 5.1, P = 0.0038).
(b) 18.72 μM: LiWTS vs LiEF2 clone 5 (t(9) = 2.67, P = 0.0257); 37.44 μM: LiWTS vs LiEF2 clone 5 (t(8) = 6.14, P = 0.0003); 74.88 μM: LiWTS vs LiEF2
clone 5 (t(9) = 4.9, P = 0.0008)
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slightly Leishmania from lethal action of EF2K inhibi-
tor. In addition, we evaluated the effect of EF2K
inhibitor on the growth of L. braziliensis lines upon
SbIII exposure. Surprisingly, the combined treatment
SbIII with EF2K inhibitor enhanced the leishmanicidal
activity against both L. braziliensis lines compared to
those incubated with SbIII or EF2K inhibitor alone
(Fig. 5b). Additionally, this increased SbIII susceptibil-
ity was higher in the EF2-overexpressing L. braziliensis
clone 9 (88% growth inhibition) than in the wild-type
L. braziliensis line (77.7% growth inhibition), suggest-
ing a possible involvement of EF2 in this activity.
Susceptibility of NDKb-overexpressing L. braziliensis lines
to H2O2
L. braziliensis clonal lines overexpressing NDKb gene
were submitted to susceptibility assays with H2O2 to
evaluate the tolerance to oxidative stress generated by
different concentrations of this compound. Our results
demonstrated that LbWTS line showed an H2O2 EC50 of
213 μM, and the LbNDKb clones 4 and 9 displayed the
same value of EC50 for H2O2, which was equal to
207 μM (Table 1). These data suggest that NDKb
enzyme is not directly involved in the defense against
oxidative stress in L. braziliensis.
Fig. 4 EC50 of lamivudine for wild-type and NDKb-overexpressing L. braziliensis lines (a) and effect of lamivudine on the growth of L. braziliensis
lines upon SbIII exposure (b). Parasites were incubated in M199 medium in the absence or presence of different concentrations of lamivudine
(C8H11N3O3S) (125 to 10,000 μM). For competition assay, cells were exposed to the EC50 of SbIII (7, 12 and 15 μM for the LbWTS and NDKb-
overexpressing clones 4 and 9, respectively) and the EC50 of lamivudine (766, 2110 and 2014 μM for the LbWTS and NDKb-overexpressing clones 4
and 9, respectively) independently or combined, followed by incubation for 48 h. The percentage of relative growth was determined using a Z1
Coulter Counter. Mean values ± standard deviations from three independent experiments in triplicate are shown. Statistical analysis was carried out
using Student’s t-test. Statistically different values are highlighted as follows: **P < 0.01; ***P < 0.001. Pairwise comparisons (a): 250 μM: LbWTS vs
LbNDKb clone 9 (t(7) = 4.04, P = 0.0049); 500 μM: LbWTS vs LbNDKb clone 4 (t(9) = 5.27, P = 0.0005); LbWTS vs LbNDKb clone 9 (t(9) = 3.74, P = 0.0046);
1000 μM: LbWTS vs LbNDKb clone 4 (t(10) = 5.67, P = 0.0002); LbWTS vs LbNDKb clone 9 (t(10) = 3.52, P = 0.0055); 2500 μM: LbWTS vs LbNDKb clone 4
(t(8) = 5.03, P = 0.0010); LbWTS vs LbNDKb clone 9 (t(8) = 3.91, P = 0.0045)
Fig. 5 EC50 of elongation factor 2 kinase (EF2K) inhibitor for wild-type and EF2-overexpressing L. braziliensis lines (a) and effect of EF2K inhibitor
on the growth of L. braziliensis lines upon SbIII exposure (b). Parasites were incubated in M199 medium in the absence or presence of different
concentrations of EF2K inhibitor (C13H15N5O3) (50 to 300 μM). For competition assay, cells were exposed to the EC50 of SbIII (7 and 14 μM for the
LbWTS and EF2-overexpressing clone 9, respectively) and the EC50 of EF2K inhibitor (173 and 211 μM for the LbWTS and EF2-overexpressing clone
9, respectively) independently or combined, followed by incubation for 48 h. The percentage of relative growth was determined using a Z1
Coulter Counter. Mean values ± standard deviations from three independent experiments in triplicate are shown. Statistical analysis was carried
out using Student’s t-test. Statistically different values are highlighted as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Pairwise comparisons (a):
100 μM: t(6) = 3.52, P = 0.0126; 150 μM: t(6) = 3.94, P = 0.0076; 200 μM: t(6) = 8.83, P = 0.0001. (b) Sb
III + EF2K inhibitor: t(4) = 11.72, P = 0.0003
Moreira and Murta Parasites & Vectors  (2016) 9:641 Page 8 of 12
Discussion
In the absence of effective vaccine against leishmaniasis,
the only way to treat and control all forms of the disease
is through the use of chemotherapy. Pentavalent antimo-
nials are considered one of the main options of
treatment; however these drugs have several toxic side
effects and high resistance rates. Drug resistance in
leishmaniasis has a multifactorial origin, involving differ-
ent factors related to host, parasite and drug [41]. Thus,
the comprehension of resistance molecular mechanisms
in Leishmania spp. is essential to identify novel drug
targets to prevent or reverse such mechanisms. Recently,
our phosphoproteomic study identified the proteins
nucleoside diphosphate kinase b (NDKb) and elongation
factor 2 (EF2) differently modulated in antimony-
resistant L. braziliensis samples [34]. The results
presented in this study corroborate with these data once
we observed that the NDKb and EF2 proteins were more
and less expressed, respectively, in the LbSbR line than
the LbWTS pair. Literature data to date provide no
functional analysis of these proteins in Leishmania.
Therefore, overexpression of NDKb and EF2 genes in
New World L. braziliensis and L. infantum species were
performed here to investigate the contribution of these
genes in antimony resistance phenotype.
NDKb is a member of the NDK family which is impli-
cated in multiple cellular processes [42]. NDKs have a
key role in the purine metabolism in pathogenic para-
sites such as Leishmania spp. and Trypanosoma spp.,
which makes these enzymes potential targets for the
development of new strategies for trypanosomiasis treat-
ment [43]. NDK, which corresponds to Nm23 gene fam-
ily in the human genome, can be considered a tumor
metastasis suppressor [44, 45]. Furthermore, it has dif-
ferential abilities to modulate tumorigenesis [46]. Here
we observed that NDKb protein is more expressed in
SbIII-resistant L. braziliensis and L. infantum lines than
in the corresponding wild-type lines. Interestingly, prote-
omic analysis showed that the NDK enzyme was more
abundant in a benznidazole-resistant Trypanosoma cruzi
population [47]. In our study, transfection of the NDKb
gene in wild-type L. braziliensis and L. infantum lines
led to increase of NDKb protein levels in the transfected
clones when compared to their parental counterparts, as
demonstrated by Western blot results. Functional assays
showed that L. braziliensis clonal lines overexpressing
this enzyme are less susceptible to SbIII in relation to
untransfected parasites. Nevertheless, no difference was
observed in the susceptibility to antimony between the
wild-type and NDKb-overexpressing L. infantum lines,
demonstrating that this gene does not alter the SbIII-re-
sistance phenotype in this species.
In our search for possible inhibitors of NDKb enzyme,
we found a drug known as lamivudine that is used in
the chemotherapy of HIV and HBV diseases. According
to DrugBank (www.drugbank.ca/drugs/DB00709), lami-
vudine is phosphorylated to active metabolites that com-
pete for integration into DNA of the virus. These
metabolites inhibit the HIV reverse transcriptase enzyme
competitively and function as a terminator of DNA
chain synthesis. The absence of a 3′-OH group in the
incorporated nucleoside analogue stops the formation of
the 5′ to 3′ phosphodiester linkage required for DNA
chain elongation, and thereby, the growth of viral DNA
is finished. Our study showed that overexpression of the
NDKb enzyme confers resistance to lamivudine. The
results propose that the parasites express the active form
of this enzyme and that lamivudine probably prevents
the transfer of γ-phosphoryl groups from NTP to NDP
in the parasite. In addition, our results revealed that the
combination lamivudine and SbIII does not alter the
leishmanicidal effect, suggesting that this combination is
not a good strategy to be used in the leishmaniasis
chemotherapy.
Attenuation of reactive oxygen species (ROS) produc-
tion is an additional function proposed for secreted
NDKs by pathogenic microorganisms [48]. Our results
revealed that overexpression of NDKb enzyme did not
alter the susceptibility of parasites to H2O2. These find-
ings suggest that NDKb enzyme is not directly involved
in the defense against oxidative stress in L. braziliensis.
Molecular mechanisms that regulate protein synthesis
are essential for various biological phenomena. Protein
translation is a process regulated at the initiation and
elongation levels. There are diverse factors responsible
for the regulation at translation elongation, but EF2
along EF1A are one of the most important enzymes
which conduct the elongation cycle of protein synthesis
in eukaryotic cells [49]. Our previous phosphoproteomic
study demonstrated that EF2 protein presented lower
abundance in SbIII-resistant L. braziliensis samples [34],
suggesting that this protein was dephosphorylated (ac-
tive state) to regulate the elongation of essential proteins
which are crucial to maintain the antimony resistance
phenotype. Other studies also found EF2 contributing to
this phenotype in different Leishmania species. EF2 was
found with higher abundance in SbV-resistant L. dono-
vani isolates [50], SbIII-resistant L. panamensis and L.
infantum lines [33, 51]. However, according our previous
results this protein probably might be dephosphorylated
in these antimony-resistant parasites. Thus, these studies
demonstrate that there are differences among Leish-
mania species, which can result in variations in the
degree of phosphorylation or expression of the EF2
protein.
In this work, we transfected the EF2 gene to analyze if
the overexpression of this enzyme contributes for SbIII
resistance in Leishmania species. Western blot assays
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revealed that the expression level of this protein was
higher in L. braziliensis and L. infantum lines overex-
pressing EF2 in comparison with their respective wild-
type counterparts. Experiments of susceptibility to
antimony showed that both L. braziliensis clones trans-
fected with EF2 gene were more resistant to SbIII than
the controls (wild-type and empty vector). On the other
hand, the EF2-overexpressing L. infantum lines did not
present difference in the susceptibility to SbIII when
compared to its parental line, showing that this gene is
not relevant to SbIII resistance in this Leishmania
species. Overexpression of EF2 was observed in patients
with lung adenocarcinoma [52] and related with reduced
cell death after exposure to cumene hydroperoxide [53].
Kushawaha et al. [54] demonstrated that EF2, a Th1
stimulatory protein of L. donovani, produces strong
IFN-γ and IL-12 response in cured Leishmania-infected
patients/hamsters and confers considerable protection
against experimental visceral leishmaniasis.
EF2 can be regulated through inhibitory phosphoryl-
ation at threonine 56 (T56) by EF2K [55]. Phosphorylation
on T56 inactivates EF2 and it is the unique known regular
EF2 functional alteration. Differently, EF2K suffers vast
regulatory phosphorylations that permit distinct pathways
to impact elongation [32]. Our results showed that EF2-
overexpressing clone showed slight resistance to the EF2K
inhibitor in comparison with the wild-type line. Surpris-
ingly, this inhibitor increased the antileishmanial effect of
SbIII, especially against EF2-overexpressing parasites. Chen
et al. [40] showed that the concentrations of this inhibitor
that effectively inhibited EF2 phosphorylation did not pro-
duce significant inhibition of cancer cell proliferation.
Our results demonstrated that both NDKb and EF2
proteins of Leishmania presented approximately 60% of
identity with the mammal proteins, indicating a good
degree of conservation between these proteins. In this
way, further studies are needed to investigate the cyto-
toxicity of lamivudine and EF2K inhibitor against mam-
malian cells.
Conclusions
Our findings represent the first study of NDKb and EF2
genes overexpression in Leishmania species, demon-
strating that these proteins are implicated in SbIII resist-
ance phenotype in L. braziliensis. Susceptibility assays
showed that NDKb-overexpressing lines were more
resistant to lamivudine, and EF2-overexpressing clone
was moderately more resistant to EF2K inhibitor. In
addition, our results suggest that the combined treat-
ment EF2K inhibitor with SbIII might be a good strategy
to increase antileishmanial effect. Therefore, our data
provided in this report bring new knowledges about re-
sistance to SbIII in Leishmania which can contribute to
develop new strategies for leishmaniasis chemotherapy.
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